1. Scrip
  2. >>Business
  3. >>Earnings

Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year

 
• By Mandy Jackson

Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.

Murdo_Gordon_1200.jpg
Amgen Commercial Chief Murdo Gordon

Amgen Inc. is at a crossroads as sales of multiple legacy products face generics, biosimilars and other competitors, while new revenue generators haven't grown enough to fill blockbuster sales gaps. Executive vice president of global commercial operations Murdo Gordon joined the company last year and is tasked with keeping Repatha, Aimovig and Evenity on the path to growth, while preventing sales of Neulasta, Enbrel and Sensipar from traveling too far south.

Gordon is likely to face the bulk of analysts' questions during the company's 30 July call to discuss second quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.